73 filings
Page 2 of 4
DEFA14A
9wro4hoqxxuwfehyae
19 Apr 23
Additional proxy soliciting materials
4:31pm
ARS
oe67j3qaej3m7 ly
19 Apr 23
Annual report to shareholders
4:29pm
8-K
b671qk4l prrx7t
5 Apr 23
Entry into a Material Definitive Agreement
4:32pm
424B5
kk1e 6e0ut
5 Apr 23
Prospectus supplement for primary offering
4:30pm
S-8
bm5 fixic17
29 Mar 23
Registration of securities for employees
5:10pm
8-K
x13h afr5xiar5yu2
29 Mar 23
Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights
4:52pm
8-K
7ktl35p ev
23 Jan 23
Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors
8:01am
8-K
8uc36
14 Nov 22
Aerovate Therapeutics Announces Third Quarter 2022 Financial Results
7:46am
EFFECT
7ow45b
24 Aug 22
Notice of effectiveness
12:15am
CORRESP
xksk2gv
19 Aug 22
Correspondence with SEC
12:00am
UPLOAD
8ntijtcm7vbmw0mexr
18 Aug 22
Letter from SEC
12:00am
S-3
il0 ge8mg790s11v8so5
15 Aug 22
Shelf registration
6:00pm
8-K
oajs1g3
15 Aug 22
Aerovate Therapeutics Announces Second Quarter 2022 Financial Results
7:55am
8-K
l35gi9pim0x0um1r
22 Jun 22
Submission of Matters to a Vote of Security Holders
5:15pm
8-K
1te8cw2wgfb7ksk8e
16 May 22
Aerovate Therapeutics Announces First Quarter 2022 Financial Results
8:00am